Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP +50.00% Equity-to-Asset is -20.61 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,416 Biotechnology companies, Regen BioPharma ranks worse than 99.29% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Regen BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-5.36 Mil. Regen BioPharma's Total Assets for the quarter that ended in Mar. 2026 was $0.26 Mil.
Therefore, Regen BioPharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was -20.61.
The historical rank and industry rank for Regen BioPharma's Equity-to-Asset or its related term are showing as below:
RGBP'
s Equity-to-Asset Range Over the Past 10 Years
Min: -200.57 Med: -25.29 Max: -0.22
Current: -20.61
During the past 13 years, the highest Equity to Asset Ratio of Regen BioPharma was -0.22. The lowest was -200.57. And the median was -25.29.
RGBP's Equity-to-Asset is ranked worse than 99.29% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs RGBP: -20.61
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Regen BioPharma Equity-to-Asset Related Terms
Regen BioPharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs IOBTQ, SCPX, LIPO: Equity-to-Asset Comparison
For the Biotechnology subindustry, Regen BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Regen BioPharma's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Equity-to-Asset of -20.61 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #1406 out of 1416 companies in the Biotechnology industry, placing it in the top 99.3%.
Is Regen BioPharma's Equity-to-Asset too high?
Regen BioPharma's current Equity-to-Asset is -20.61. Based on the distribution chart, Regen BioPharma ranks #1406 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Equity-to-Asset compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #1406 out of 1416 companies for Equity-to-Asset. This places Regen BioPharma in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Equity-to-Asset is -20.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current Equity-to-Asset is -20.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Equity-to-Asset is -20.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
